Navigation Links
InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery
Date:12/4/2009

InhibOx, a leading developer of novel and effective computational methods for drug discovery, has joined forces with MolPort, an innovator in rare chemical trading. MolPort focuses on developing rare chemical trading platform and builds database of commercially available compounds. Now we provide this database and its updates to computational chemists at InhibOx where they incorporate it into the virtual screening procedures. Once they identify suitable lead candidates, MolPort offers to efficiently source these compounds and deliver to the client for testing.

(PRWEB) December 4, 2009 -- InhibOx Ltd (Oxford, UK) and MolPort Ltd (Riga, Latvia) announce a strategic partnership to deliver integration in library design and compound provision.

InhibOx, a leader in drug lead identification and library design software and service, uses breakthrough proprietary technology to offer an on-demand virtual screening capability which has demonstrated dramatically improved results over traditional high throughput screening methods. The company has partnered with MolPort, the innovative compound provision consolidator/specialist.

Together, the two companies are able to provide a new, unique service which delivers novel lead candidates in the form of a rich data set and high quality compound samples. Frequently virtual screening identifies compound sets for testing which must be sourced from multiple suppliers, imposing a logistical problem, especially for smaller companies. This integrated service removes these bottlenecks, allowing much improved access to commercially available molecules.

Dr. Paul Finn, CEO of InhibOx, sees this as an important breakthrough in outsourced screening services. “InhibOx goes further than anyone else in value-added virtual screening, and the results bear this out. By adding library sample provision to the service, through MolPort’s highly responsive capability, we offer a unique integrated service which accelerates lead design and lowers the management costs for all customers”.

“Our goal is to make chemical buying as simple as buying a book on Amazon. Screening compound sourcing can be especially complex as it often involves locating suppliers for a large number niche products form companies all around the world. Integrating our database of commercially available compounds with InhibOx virtual screening processes enables streamlining of the road from idea to testable compounds in the clients laboratory. Partnering with InhibOx has allowed us to tailor our services for the needs of computational chemists.” said Dr. Imants Zudans, CEO of MolPort.

About InhibOx:

InhibOx develops novel and effective computational methods for drug discovery to improve the productivity of lead and candidate identification. The company was founded by Professor W. Graham Richards, former Chairman of Chemistry at the University of Oxford and world leading computational chemist. The company grew from the outstandingly successful Screensaver Lifesaver project which involved some 3.5 million personal computers in over 200 countries: the world's biggest computational chemistry experiment finding lead compounds to inhibit cancer targets, anthrax and smallpox. Since then, InhibOx has built up a significant technology platform in computer-aided drug design. Ongoing activities comprise the development of entirely novel computational drug discovery methods; the development of Scopius, a very large and carefully curated database of commercially-available and virtual chemical structures and their delivery to the life science industries.

About MolPort:

MolPort is a rare chemical compound marketplace enabling worry free centralized ordering of chemicals from over 200 companies. To make the marketplace work MolPort has created a world class database of commercially available chemical compounds. The free access online search portal www.molport.com features unmatched advanced chemical structure search capabilities that are especially suited for a sophisticated and demanding user.

# # #

Read the full story at http://www.prweb.com/releases/2009/12/prweb3298024.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. St. Jude Patients and Expert Chefs Join Forces To Create Gingerbread House
2. LeapFish and Make-a-Wish Foundation Join Forces to Raise $10,000 and Tweet an Ill Child's Wish True
3. Big Brothers Big Sisters Military Mentor Featured in New Civic Enterprises Report on Leadership and Our Armed Forces
4. Drug industry, nonprofits join forces to fight worlds neglected diseases
5. U.S. Army Special Forces Operators Reluctant to Seek Treatment for Posttraumatic Stress Disorder
6. Childrens and Its Physicians Join Forces With Insurers to Accelerate Transformation of Pediatric Care to a More Effective and Efficient Health Care Delivery System
7. MTD Joins Forces with the AHA to Promote Heart Health
8. Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse
9. Engineering center to probe forces that cause cancer to spread
10. Substance Abuse Expert Dr. Drew Joins Forces with the Five Moms to Raise Awareness About OTC Cough Medicine Abuse Among Teens
11. Ford and Labor Leaders Join Forces with March of Dimes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 
(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... advocates will discuss how to improve care by making data on heart procedures ... disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital Heart ...
(Date:2/11/2016)... ... ... In a new paper published in the latest issue ... Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage in ... this vital area. , The upper lateral cartilage in rhinoplasty, refers to a ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... unparalleled clinical decision support technology, with highly adaptable algorithms, has been updated to ... patient has signs and symptoms consistent with Zikas and a travel history to ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... motivational speaker, trainer and author Ray Clarke poses a question as a challenge ... . In his book, "Being in the Being" (published by Partridge Singapore), Clarke ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016 Potrero ... system, is pleased to announce the appointment of George ... San Antonio, TX , WellMed is ... servicing over 200,000 patients and HMO members in ... founding WellMed in 1990 out of his own internal medicine ...
(Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
(Date:2/11/2016)... , Ill. and INDIANAPOLIS , Feb. 11, ... many young people, but for those with type 1 ... do these students juggle class schedules, assignments and campus ... with type 1 diabetes. On top of that, many ... Diabetes Scholars Foundation (Foundation) Lilly Diabetes ...
Breaking Medicine Technology: